One great example of a “what the hell is happening here” story run just the other day that opened with, “Orange juice, known ...

Replimune Group's RP1 oncolytic virus therapy faced an FDA rejection, raising concerns about the platform's viability in ...

One of the most notable accomplishments of the first Trump Administration was its willingness to take on the status quo of ...

Sarepta Therapeutics (SRPT) stock in focus as report says company hired a Trump-linked lobbying firm after deaths linked to ...

New evidence of effectiveness is cause to drop a Biden restriction on Medicare coverage for anti-amyloid treatments.

While many officials and scientists embrace other parts of the secretary’s agenda, his stance on vaccines is alienating ...

This may sound familiar if you’re subscribed to my AI Prognosis newsletter, but it’s worth repeating: I finally found time to ...

This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to ...

An investigation by Sens. Ron Wyden and Elizabeth Warren is another setback for UnitedHealth, which recently laid out a lower ...

Laura Loomer has been dubbed “Trump’s Rasputin” as her influence grows with her quest to oust administration officials she ...

Dewpoint Therapeutics, a startup working in the once-buzzy field of biomolecular condensates, has laid off most of its staff.

Eli Lilly said this morning that its experimental obesity pill orforglipron fell short of expectations in a late-stage trial, delivering 11.2% weight loss over 72 weeks — less than the 15% to 21% ...